Kimberly Levasseur F

Final take away points -

#NCSpharmJC @karenccrx @ETNCCRX @AJWPharm Impact to practice? Per Dr. Wendel

#NCSPharmJC The study population

#NCSpharmJC Methodology of the medications and monitoring:

Who was included/excluded?

What was studied? #NCSpharmJC @karenccrx @ETNCCRX @AJWPharm

You may remember reading...

Why is this a problem - let's remember what DDVP can do... @karenccrx @ETNCCRX @AJWPharm

Onto the next journal article discussion! #NCSPharmJC

Dr. Parsons' Take away: OPTION is unique in focusing specifically on non-large vessel occlusion strokes; whereas TRACE-III focused on LVO without thrombectomy and HOPE included mixed vessel populations.

#NCSPharmJC Where should we go from here?

#NCSPharmJC @karenccrx @ETNCCRX @AJWPharm What about safety